Back to top
more

Outlook Therapeutics, Inc. (OTLK)

(Delayed Data from NSDQ)

$0.64 USD

0.64
9,480,879

0.00 (0.59%)

Updated Aug 28, 2026 04:00 PM ET

After-Market: $0.65 +0.01 (0.79%) 5:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (166 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

by Zacks Equity Research

Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.

Zacks Equity Research

Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Oncobiologics (OTLK) delivered earnings and revenue surprises of +4.35% and -101.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

by Zacks Equity Research

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

Zacks Equity Research

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Buy Stocks for July 30th

by Zacks Equity Research

BYD, ROKU, OTLK, E and PII have been added to the Zacks Rank #1 (Strong Buy) List on July 30, 2025.

Zacks Equity Research

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

by Zacks Equity Research

Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.

Zacks Equity Research

All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy

by Zacks Equity Research

Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

by Zacks Equity Research

Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.

Zacks Equity Research

Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More

by Zacks Equity Research

Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.

Zacks Equity Research

Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate

by Zacks Equity Research

Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.